Novo Nordisk Brings Renewed Education Efforts, But Not New Products, To Japan In 2012
This article was originally published in PharmAsia News
Executive Summary
Novo Nordisk pushes the benefits of early diabetes treatment to spur Victoza and insulin growth.
You may also be interested in...
More Insulin Innovation To Come, Says Novo CEO Sorensen
Market-leader Novo is confident it can continue to innovate in insulin – and command premium prices
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.